Our Team

Management Team

scan0003-2Dr. Rashida A. Karmali (Founder of TTI) earned her Ph.D in Biochemistry from the University of Newcastle upon Tyne in 1976. She received an M.Sc. in Animal Nutrition from the University of Aberdeen and a B.S. in Biochemistry from Makerere University (Kampala, Uganda). She obtained her JD and an MBA degree at from Rutgers University.

Dr. Karmali carried out studies on the role of eicosanoids in cancer immunotherapy and autoimmune diseases with Dr. Robert A. Good at the Memorial Sloan-Kettering Cancer Center in New York City, and then at Rutgers University in New Brunswick where she held a five-year academic position as Associate Professor.

Dr Karmali’s experience in the field of cancer includes an extensive research program described in more than 100 publications, reviewing grants and publications for, among others, the Food and Drug Administration and the American Cancer Society. In addition, she was featured on the cover of Cancer Research in December of 1997 for recognition of her work involving cyclooxygenase- 2 (COX-2) in cancer.

She specialized in intellectual property law and worked on patent litigation cases (Glaxo v. Novopharm, Glaxo v.Genpharm, Eli Lilly v.Barr Labs, Merck v.Monsanto) and IPOs and Tech transactions at leading law firms in New York. Since 2000, she has run a solo law office on Wall Street.

She is registered to practice in NY, is a Registered Patent Agent, and a Certified Licensing Professional (CLP). She is a Member of AACR, ACS, ASCO, AIPLA, ABA, and LES.

Since 2005 Rashida has held the position of Chief Executive Officer, President, & Director, at Tactical Therapeutics, Inc. She is assisted by an Experienced Management Team of Part-time Experts and Scientific Advisors.

 

Scientific Advisory Board

Scientific Consultant — John G. Page, Ph.D., D.A.B.T., Rockhill Toxicology Consultants
Scientific Advisor — Gregory Gorman, Ph.D., Pharmaceutical Sciences, Samford University
Scientific Advisor — Yulia Maxuitenko, Ph.D., Preclinical Oncology, Consultant, previously at Southern Research Institute
Scientific Advisor — Stephen R. Byrn, Ph. D., Purdue University
Scientific Regulatory Advisors — Beckloff Associates, Inc.

 

Experts in the Field of Glioblastoma

Key Opinion Leaders in the field of drug discovery and glioblastoma clinical experts have lined up behind the clinical results and are rallying Dr. Karmali to seek funding as soon as possible.

Experts in Drug Development

Dr. Steven Byrn – Professor of Medicinal Chemistry, Purdue University
Dr. Greg Gorman – Samford University School of Pharmacy, Scientific Advisor for Tactical Therapeutics since 2006

Experts in Clinical Oncology & Collaborators in CTO Clinical Trials

Dr. Antonio Omuro – Neuro-oncologist, PI, Memorial Sloan-Kettering Cancer Center
Dr. Annick Desjardins – Associate Professor, Neuro-Oncologolist, Duke University Medical Center
Dr. Roger Stupp – Neuro-Oncologist, University of Zurich, Switzerland
Dr. Elizabeth DeAngelis – Head of Brain Cancer at Memorial Sloan-Kettering Cancer Center
Dr. Sridharan Gururangan – Pediatric Neuro-Oncologist, Duke University Medical Center
Dr. Jeffrey Allen – Head of Pediatric Oncology, Neuro-oncologist, NYU Langone Med Center
Dr. Arjun Saghal – Radiation Oncologist Sunnybrook Hospital, Toronto General Hospital
Dr. James Perry – Neuro-Oncologist, Sunnybrook Hospital, Toronto General Hospital
Dr. Carmen Balana — Neuro-oncology, Catalan Institute of Oncology in Barcelona
Dr. Susan Chang/Nicholas Butowski– Neuro-oncology, UCSF, San Francisco
Dr. P-Y- Dietrich– Neuro-Oncologist, University of Geneva, Switzerland
Dr. Manmeet Ahluwalia – Director, Brain Metastases, Cleveland Clinic
Dr. Tulika Ranjan – Neuro-oncologist, Cancer Institute, Allegheny General
Dr. Minesh Mehta – Radiation Oncologist, Miami Cancer Institute
Dr. Andrew Lassman – Chief, Neuro-oncology, NY Presbyterian/Columbia Univ.
Dr. Patrick Wen – Director, Neuro-oncology, Dana Farber Cancer Center